Inhibition of intimal hyperplasia using antibodies to PDGF recep

Details Inhibition of intimal hyperplasia using antibodies to PDGF recep Inhibition of intimal hyperplasia using antibodies to PDGF recep

1995-06-07

1999-11-02

Feisee, Lila

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

4241301, 4241331, 4241351, 4241411, 4241581, 514 56, A61K 39395, A61K 31725

Patent

active

059765348

ABSTRACT:
Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The anti-PDGF receptor antibodies may optionally be administered coordinately with heparin, whereby the coordinately administered antibody and heparin are combinatorially effective in inhibiting intimal hyperplasia.

REFERENCES:
patent: 5155027 (1992-10-01), Sledziewski et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5250519 (1993-10-01), Conrad et al.
patent: 5268358 (1993-12-01), Fretto
Clowes et al., Circulation Research 58(6): 839-845, 1986.
Harris et al. Tibtech 11:42-44 (1993).
Mullins et al. Interior Scler. Thromb. 14: 1047-1055 (1994).
Defendis DN+ P 5: 49-51 (1992).
Kelly et al. J. Biol Chem 266: 8987-8992 (1991).
Kawahara et al. Biochem Biophys Res. Commun. 147: 839-847.
Ostman et al. J Cell Biol 118 509-519 (1992). (Abstract Only) (1987).
Geary et al. Circulation 91: 2972-2981 (1985).
Currier et al., JACC 17(6): 118B-125B, 1991.
Schmid et al., Seminars in Thrombosis and Hemostasis 19 Suppl. 1,: 155-159, 1993.
Edelman et al., Proc. Natl. Acad. Sci. U.S.A. 87: 3773-3777, 1990.
Rubin et al., The Lancet 1(8599): 1353-1356, 1988.
Ferns et al., Science 25: 1129-1132, 1991.
Lindner et al., J. Clin. Invest. 85: 2004-2008, 1990.
Jawien et al., J. Clin. Invest. 89: 507-511, 1992.
Lindner et al., J. Clin. Invest. 90: 2044-2049, 1992.
Popma et al., Circulation 84(3): 1426-1436, 1991.
Ferrell et al., Circulation 85(4): 1630-1631, 1992.
Reilly et al., J. Cell. Phys. 136: 23-32, 1988.
Guyton et al., Circulation Research 46(5): 625-634, 1980.
Cavari et al., Cell Biology International 17(8): 781-786, 1993.
Kimura et al., Japan. J. Pharmacol. 59: 51-56, 1992.
Castellot, Jr. et al., J. Cell. Biol. 109(6): 3147-3155, 1989.
Bioworld Today 5(4): 1,3; 1994.
Buchwald et al., Circulation 86(2): 531-537, 1992.
Preisack et al., European Heart Journal 14(1): 187-192, 1993.
Violaris et al., British Journal of Hospital Medicine 49(1): 37-43, 1993.
Berk et al., JACC 17(6): 111B-117B, 1991.
Clowes, Circulation 86(5): 1657-1658, 1992.
Preisack et al., Blood Coagulation and Fibrinolysis 4(1): S55-S58, 1993.

Affiliated with

Also associated with

Rating

Inhibition of intimal hyperplasia using antibodies to PDGF recep does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of intimal hyperplasia using antibodies to PDGF recep, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of intimal hyperplasia using antibodies to PDGF recep will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2131448